pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,595 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1772Endpoints1378Fierce Biotech697BioSpace689BioPharma Dive522raps231onclive165fda recalls111
therapy area
allOncology12280Rare Disease3178Immunology2859Cardiology2719Hematology2154Pulmonology2135Vaccines
  • UK regulator to shift from one-off checks to continuous monitoring of AI medical devices
    The UK’s Medicines and Healthcare products Regulatory Agency announced a new policy that will require continuous monitoring of AI‑driven medical devices, replacing the current one‑time review model…
    Fierce Biotech · 1mo agoRegulatoryPositive↗ source
  • Caribou Biosciences halts pipeline and announces major workforce cut
    Caribou Biosciences, a Bay Area biotech that develops off-the-shelf CAR-T cell therapies, said it will stop all clinical development and begin a substantial workforce reduction. The company, which…
    Fierce Biotech · 1mo agoLayoffsNegative↗ source
← prev
page 43 of 184
next →
fda medwatch109
globenewswire health73
fda press59
1787
Psychiatry & CNS1200
Ophthalmology1036
Endocrinology & Metabolism775
Pain768
Nephrology758
  • AstraZeneca opens 570,000-sq-ft R&D campus in Cambridge, targeting 2,000 staff
    AstraZeneca inaugurated a new research and development building in Cambridge, Massachusetts on Monday. The facility spans 570,000 square feet and is expected to house about 2,000 employees once fu…
    Endpoints · 1mo agoPositive↗ source
  • ArriVent's lead lung cancer drug firmonertinib fails Phase 3 trial, shares plunge
    ArriVent BioPharma announced that its flagship EGFR inhibitor, firmonertinib, did not meet primary endpoints in a late-stage Phase 3 study for lung cancer. The trial results were released on Octobe…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • AstraZeneca launches $1 billion R&D hub in Boston’s Kendall Square
    AstraZeneca opened a new research and development site in Kendall Square, Boston, marking a $1 billion investment in the U.S. biotech corridor. The Boston location underscores the company’s commit…
    STAT · 1mo agoNeutral↗ source
  • U.S. government launches first federally funded ibogaine trials for opioid addiction and PTSD
    The Trump administration announced the start of the United States' first government‑funded clinical trials of ibogaine, a psychedelic compound being investigated for its potential to treat opioid u…
    STAT · 1mo agoRegulatoryPositive↗ source
  • Compliance worries keep AI adoption in drug manufacturing low, survey finds
    A new survey of more than 400 research and manufacturing professionals shows that over 90% of drugmakers have not committed to expanding AI use in regulated drug production. While AI is widely em…
    BioSpace · 1mo agoRegulatoryNegative↗ source
  • AI investments in healthcare delivering returns faster than executives anticipated
    A new report from Bessemer Venture Partners finds that artificial-intelligence projects in health-care are delivering benefits more quickly than industry leaders expected. The survey highlights th…
    Endpoints · 1mo agoPositive↗ source
  • ArriVent’s phase 3 EGFR inhibitor trial misses primary endpoint, shares plunge 57%
    ArriVent BioPharma reported results from its phase 3 Furvent trial, which evaluated firmonertinib, a brain-penetrant EGFR inhibitor, in patients with exon 20 insertion-mutated non-small cell lung c…
    Fierce Biotech · 1mo agoNegative readoutNegative↗ source
  • Kairos pushes prostate cancer drug ENV-105 into earlier treatment line after promising mid-phase data
    Kairos Pharma announced a change to its phase 2 trial of ENV-105, a prostate cancer candidate, moving it to an earlier line of therapy. The modified protocol will enroll patients whose PSA rises a…
    Fierce Biotech · 1mo agoPositive readoutPositive↗ source
  • Experts warn FDA against approving Grail’s ineffective multicancer blood test
    Physician and cancer‑screening researcher H. Gilbert Welch argues that the FDA should not greenlight Grail’s multicancer blood test, noting the company’s trial of 140,000 participants used a weak s…
    STAT · 1mo agoRegulatoryNegative↗ source
  • Lycia Therapeutics files for IPO to fund antibody degrader platform
    Lycia Therapeutics, a protein‑degradation startup built on research from Nobel laureate Carolyn Bertozzi, announced it has filed for an initial public offering. The filing is intended to raise cap…
    Endpoints · 1mo agoDealNeutral↗ source
  • Abbott receives FDA clearance for CardioMEMS HF System updates enabling home pressure monitoring via smartphone app
    Abbott announced that the U.S. Food and Drug Administration has cleared updated software for its CardioMEMS HF System. The changes add a patient facing component through the CardioGuide HF mobile a…
    Fierce Biotech · 1mo agoApprovalPositive↗ source
  • AstraZeneca opens 570,000-sq-ft Kendall Square R&D hub to boost cancer and biotech research
    AstraZeneca inaugurated a 570,000-square-foot research and development facility in Kendall Square, Cambridge, Massachusetts. The 18-story building will host roughly 2,000 scientists working on chr…
    Fierce Biotech · 1mo agoPositive↗ source
  • BioSpace honors 40 emerging leaders shaping biopharma with breakthroughs in mRNA, gene and cell therapies
    BioSpace announced its latest 40 Under 40 cohort, recognizing young professionals who have made notable contributions across biopharma. The honorees span a range of roles, from scientific innovator…
    BioSpace · 1mo agoPositive↗ source
  • Utah expands AI prescribing sandbox to boost health‑tech innovation
    Utah is positioning itself as a national leader in the use of artificial intelligence for healthcare, according to recent reporting. The state’s Office of AI Policy runs a regulatory sandbox that…
    Endpoints · 1mo agoRegulatoryPositive↗ source
  • KymaThera secures $80M Series B to advance oral PI3Kα inhibitor K-1728 as biotech peers raise funds and go public
    KymaThera, a San Diego biotech, announced an $80 million Series B round to fund development of its pan-mutant selective PI3Kα inhibitor, K-1728. The oral candidate is planned to enter Phase 1 clin…
    Endpoints · 1mo agoDealPositive↗ source
  • Doctor warns AI-driven documentation may boost hospital bills without improving care
    A resident physician writes that recent Blue Cross Blue Shield research has sparked anger by suggesting hospitals use AI tools to increase charges without adding care. The study claims hospitals e…
    STAT · 1mo agoNegative↗ source
  • Hospitals Launch Cash‑Pay Longevity Clinics, Offering Intensive Health Monitoring
    Prestigious hospitals across the United States have begun offering cash‑pay longevity programs that promise comprehensive health monitoring for patients willing to spend thousands of dollars out of…
    STAT · 1mo agoNeutral↗ source
  • FDA outlines roadmap for AI guidance to be released in 2027
    The Food and Drug Administration announced a roadmap for new artificial intelligence guidance that it plans to publish in 2027. The upcoming guidances are expected to establish a framework for dev…
    STAT · 1mo agoRegulatoryNeutral↗ source
  • Trump proposes $90 monthly aid for seniors as stem cell therapies gain attention
    STAT's D.C. Diagnosis newsletter notes that stem cell treatments are being discussed as a possible next breakthrough in medicine, likening them to the rise of peptide therapies. President Trump an…
    STAT · 1mo agoNeutral↗ source
  • Nuvig Therapeutics pauses CIDP trial of NVG-2089, cites enrollment and cost challenges
    Nuvig Therapeutics, backed by major pharmaceutical partners, announced it is stopping development of its lead fusion protein NVG-2089 for chronic inflammatory demyelinating polyradiculoneuropathy (…
    Fierce Biotech · 1mo agoNegative↗ source
  • Nonprofit hospitals launch pricey longevity clinics offering personalized health assessments
    Longevity clinics, which promise individualized health advice and advanced testing, are now being opened by major nonprofit hospitals. The services aim to map the health trajectories of patients ac…
    STAT · 1mo agoNegative↗ source
  • Study finds pulse oximeters at Johns Hopkins shifted from overestimating to underestimating oxygen, with larger errors in patients of color
    A retrospective analysis of five years of pulse‑oximeter data from Johns Hopkins Hospital shows a shift in measurement bias. Earlier research documented that the devices tend to overestimate oxyge…
    STAT · 1mo agoNeutral↗ source
  • Infectious disease expert urges calm over mysterious pneumonia case in Siberia
    A 28‑year‑old laboratory worker at a Siberian institute that studies plague died after developing severe pneumonia, prompting a quarantine of a nearby hospital and monitoring of roughly 200 contact…
    STAT · 1mo agoNeutral↗ source